2010 Press Releases
December 10
QLT Announces Toronto Stock Exchange Approval of Share Repurchase Program
PDF version
December 08
QLT Announces Share Repurchase Program
December 07
QLT Receives Orphan Drug Designation for QLT091001 to Treat Retinitis Pigmentosa
QLT Receives Orphan Drug Designation for QLT091001 to Treat Leber Congenital Amaurosis
November 29
QLT Ophthalmics, Inc. Establishes an Activis PDT Laser Co-Promotion Agreement with Quantel Medical and Quantel USA in the United States
November 3
QLT Announces Third Quarter Results for 2010
October 28
QLT Announces Expansion of Phase 1b Study of Oral Synthetic Retinoid Compound
July 27
QLT Announces Second Quarter Results for 2010
June 28
QLT Added to the Russell Global Index
June 22
QLT Announces Final Results From Its RADICAL Study Evaluating Verteporfin PDT (Visudyne®) Combination Therapy in Exudative AMD
June 15
12-Month Results from DENALI Study Evaluating Verteporfin PDT (Visudyne®) Combination Therapy
May 21
QLT Announces Toronto Stock Exchange Approval of Increased Share Repurchase Program
May 20
QLT Announces Its Intention to Increase Share Repurchase Program
May 6
QLT Announces First Quarter Results for 2010
April 20
QLT Announces Positive Interim Results From Phase 1b Study of its Oral Synthetic Retinoid Compound in Leber Congenital Amaurosis
April 12
QLT Names Dipak Panigrahi, M.D., Chief Medical Officer
March 10
QLT Announces Fourth Quarter and Year End 2009 Results
QLT Announces Phase II Clinical Trial Results and Development Plans for the Punctal Plug Delivery System
February 22
QLT Names Joseph L. Turner to the Board of Directors
